Latest Conference Articles

Christine Barrett, PharmD, BCOP, shares insights, challenges, and advice for oncology pharmacists navigating neoadjuvant therapy.

Scott A. Soefje, PharmD, MBA, BCOP, explained how the expanding use of the FDA’s 505(b)(2) drug approval pathway is creating operational and reimbursement challenges for oncology infusion centers.

Jessica Davis, PharmD, BCOP highlights the role of pharmacy technicians in ambulatory oncology clinic settings.

Nipocalimab with standard of care helped patients with generalized myasthenia gravis (gMG) maintain improvements in daily living and quantitative scores compared with placebo.

These data provide compelling evidence to revise existing transfusion protocols, recommending 4F-PCC as the preferred treatment for hemostatic management in cardiac surgery.

Lauren Dietz, PharmD, highlighted the role of oncology pharmacists in guiding prophylaxis decisions to optimize transplant outcomes.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.

Christine Barrett, PharmD, BCOP, addressed advances in the treatment of stage III melanoma that provide the potential to improve long-term outcomes by enhancing immune response, tailoring surgical approaches, and refining patient selection strategies.

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.

Amir Ali, PharmD, BCOP, and Alison Hsieh, PharmD share insights from their presentation about cytokine release syndrome, ICANS, and CAR T-cell therapy.

Alexandra Wolff, PharmD, BCOP, FHOPA, was awarded a fellow of HOPA at the 2025 annual meeting.

Mya Tran, PharmD, BCOP, offers insights for navigating the complex treatment landscape for non-small cell lung cancer.

Michael Arnold, PharmD, discussed the role of oncology pharmacists in enhancing biomarker testing for patients with metastatic colorectal cancer.

The future holds the promise of earlier diagnosis, more targeted therapies, and personalized neurological care, said speaker William D. Freeman, MD, FAAN.

Huntington disease (HD) has no curative treatments, therefore, there is a great need for therapies that can reduce or slow the progression of symptoms.

Matthew Lei, PharmD, BCOP, highlights the value of community, collaboration, and innovation at the HOPA Annual Conference.

Nilufer Ertekin-Taner contrasts current one-size-fits-all Alzheimer disease treatments with the promise of precision medicine and emphasizes the vital role of collaborative, multidisciplinary care.

Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib.

The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.

Numerical differences were observed as early as Month 1.

Sophie Jabban discusses research presented at the SGO Annual Meeting highlighting significant disparities in MRI access for patients with cervical cancer receiving chemoradiation, with delays linked to both race and insurance status, underscoring systemic barriers that may impact timely treatment.

Pharmacy professionals gathered at the American Pharmacists Association 2025 Annual Meeting and Exposition and discussed critical insights in interviews with Pharmacy Times®.

Advanced practice provider (APP) care models allow for health systems to better individualize care for patients, effectively meeting their needs.

Kara Melmed, MD, emphasizes the critical importance of rapid, team-based intervention for intracerebral hemorrhage (ICH) patients, with pharmacists playing a key role in blood pressure management.

Pharmacists are essential navigators in the complex landscape of gene therapy.

Kayla Johnson, PharmD, BCPS, BCPP, highlights how integrating pharmacists into neurology clinics drives significant cost savings, high intervention acceptance rates, and improved care coordination.

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Sophie Jabban discusses findings from 2 studies that highlight how geographic location, race, ethnicity, and social determinants of health contribute to delays in initiating chemoradiation for patients with cervical cancer.

Stephanie Miller, PhD discusses how artificial intelligence can revolutionize medical research by assisting in drug development and potentially providing more targeted treatments across various diseases.

Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.